Key facts
- Ultromics’s last known valuation is $131.0M (Jul 2025).
- It has raised $135.8M; the latest was Later Stage VC ($64.6M) in Jul 2025.
- Notable investors include GV, Tech Nation Group, Future Planet Capital, University of Oxford, Lightrock — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Ultromics
- ·The full record, as it builds
Funding rounds
No funding rounds for Ultromics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ultromics
Developer of an artificial intelligence-based cardiovascular diagnostic technology designed to detect heart failure and amyloidosis. The company offers machine learning models applied to electrocardiogram data to extract clinically relevant patterns, enabling clinicians to improve diagnostic accuracy and make informed decisions from complex cardiac signals.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2017
- Employees
- 78
- Website
- ultromics.com/
- Ownership
- Privately Held (backing)
Ultromics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ultromics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ultromics in its N-PORT filings yet. We sweep new filings monthly.